Bharat Biotech vaccine shows 77.8% overall efficacy, 65% against Delta variant
Hyderabad-based Bharat Biotech has just published the trial data for its Covid-19 vaccine, Covaxin, which claims the India-made vaccine to be 77.8 per cent effective against the coronavirus. The vaccine was found to have 93 per cent efficacy against severe cases of Covid-19 and 63 per cent efficacy against asymptomatic transmission.
Trial data also indicated that the vaccine was effective against the Delta variant of the virus. "BBV152 conferred 65.2% protection against the SARS CoV 2 Variant of concern, B.1.617.2 (Delta)," the release from Bharat Biotech to the media said.